Page 18 - Cipla
Cipla surges 5% on USFDA approval for dimethyl fumarate DR capsules
The drug, indicated for treatment of relapsing forms of multiple sclerosis, had annual US sales of US$3.8 billion as per IQVIA MAT July 2020.
 "Cipla surges 5% on USFDA approval for dimethyl fumarate DR capsules")
Cipla gets final approval from USFDA for multiple sclerosis drug
Drug major Cipla on Friday said it has received final approval from the US health regulator for Dimethyl Fumarate capsules, indicated for the treatment of relapsing forms of multiple sclerosis. The newly approved product is a generic therapeutic equivalent version of Biogen IDEC Inc's Tecfidera. Cipla has received final approval for its abbreviated new drug application (ANDA) for Dimethyl Fumarate DR (delayed release) capsules in the strengths of 120mg, 240mg and 120mg and 240mg from the United States Food and Drug Administration (USFDA), the company said in a regulatory filing. Quoting IQVIA (IMS Health) data, Cipla said Tecfidera had US sales of approximately USD 3.8 billion for the 12-month period ending July 2020. Shares of Cipla were trading 2.12 per cent higher at Rs 748.35 apiece on the BSE.
New Covid-19 drugs provide additional fuel as Cipla fires on all cylinders
Firm domestic sales and positive outlook in the US point to robust earnings
 "New Covid-19 drugs provide additional fuel as Cipla fires on all cylinders")
BSE Healthcare index hits record high; Laurus Labs, Dr Reddy's at new highs
Lupin, Stride Pharma, Neuland Labs, Lincoln Pharma, and Hikal hit their respective 52-week highs on the BSE
 "BSE Healthcare index hits record high; Laurus Labs, Dr Reddy's at new highs")
Family companies weathering Covid-19 pandemic storm better than peers
Such businesses outperform non-family firms by 3% in first six months of CY20, says Credit Suisse report
 "Family companies weathering Covid-19 pandemic storm better than peers")
Pharmacy consolidation may disrupt domestic drug market: Credit Suisse
The report says if chemists are allowed to replace doctor's prescription with a generic drug, firms with high exposure to chronic therapeutic drugs will be impacted more
 "Pharmacy consolidation may disrupt domestic drug market: Credit Suisse")
Nifty Pharma index rallies nearly 3%; Lupin surges 10%, Cipla, Cadila up 3%
All the 10 constituents of the Nifty Pharma index were trading in the green.
 "Nifty Pharma index rallies nearly 3%; Lupin surges 10%, Cipla, Cadila up 3%")
Cipla tweaks management structure to mobilise second level of executives
Do these changes augur well for the future business growth plans? Analysts think so
 "Cipla tweaks management structure to mobilise second level of executives")
India's supply of remdesivir is stabilising after shortages: Cipla
Cipla's launch of remdesivir in late June, along with subsequent launches by others, has helped ease supply bottlenecks in India
 "India's supply of remdesivir is stabilising after shortages: Cipla")
Cipla hits record high on strong Q1 result; Morgan Stanley sees 30% upside
Mumbai headquartered pharma firm posted 20% growth in profit before tax for the first quarter of the current financial year to Rs 799 crore, on a 9% YoY growth in revenues to Rs 4,346 crore
 "Cipla hits record high on strong Q1 result; Morgan Stanley sees 30% upside")
'Quality' stocks come at a premium, valuations have crossed pre-Covid level
The P/E for Bharti Airtel and Avenue Supermarts is currently below the pre-Covid levels. Reliance Industries, Cipla, Havells India, and Eicher Motors have seen the maximum P/E expansion
 "'Quality' stocks come at a premium, valuations have crossed pre-Covid level")
Cipla Q1 pre-tax profit jumps 20% to Rs 799 crore on strong revenues
Firm's domestic business did well, up 16% YoY during the quarter when Cipla launched licensed version of Gilead's remdesivir
 "Cipla Q1 pre-tax profit jumps 20% to Rs 799 crore on strong revenues")
Goa coronavirus update: State to start administering remdesivir to patients
Goa's Health Ministry received 1,008 vials of Remdesivir from pharma major Cipla
Collaborating with govt agencies to develop treatment for Covid-19: Cipla
The company is offering drugs, which have shown potency in treating Covid-19, in partnership with its global partners
Cipla witnesses 3 senior-level exits including India biz CEO Nikhil Chopra
The company's rich legacy of care and strong sense of purpose rooted in a culture of meritocracy and high performance standards have made Cipla an employer of choice for several industry leaders
Big shake-up: Cipla sees 3 big exits from top management of India business
Those who have left include India business head Nikhil Chopra
 "Big shake-up: Cipla sees 3 big exits from top management of India business")
Covid-19: Favipiravir triggers a price war; new brand launched at Rs 39
According to industry insiders, many more brands are lined up for launch, including one from Cipla
 "Covid-19: Favipiravir triggers a price war; new brand launched at Rs 39")
Cipla gets DCGI approval to sell Covid-19 drug favipiravir in India
Cipla said it would launch favipiravir as "Ciplenza" in the first week of August, priced at 68 Indian rupees (91 cents) per 200 mg tablet
 "Cipla gets DCGI approval to sell Covid-19 drug favipiravir in India")
Cipla, Amgen settle case involving generic cinacalcet hydrochloride tablets
Drug major Cipla said it has reached settlement with Amgen Inc on pending litigation involving generic cinacalcet hydrochloride tablets
Covid-19 treatment: A lowdown on possible cure and drugs being used
Business Standard takes a look at the common drugs that are being used in India for treating Covid-19 patients
 "Covid-19 treatment: A lowdown on possible cure and drugs being used")